Evidence map›Paper›PMID 42538851›Full record

ArticleEuropean journal of neurology2026

Long-Term Cancer and Mortality After Thymectomy.

Shahar Shelly, Mor Ani, Christopher Klein, Yuebing Li, Henry Kaminski, Gil I Wolfe, Keren Miron, Roni Ramon-Gonen

Abstract read
In one paragraph

Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shahar ShellyRappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.ORCID https://orcid.org/0000-0002-3585-1687
Mor AniDepartment of Neurology, Rambam Medical Center, Haifa, Israel.
Christopher KleinDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-4012-8856
Yuebing LiDepartment of Neurology, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-4248-8927
Henry KaminskiDepartment of Neurology & Rehabilitation Medicine, George Washington University, Washington, DC, USA.ORCID https://orcid.org/0000-0002-8195-0141
Gil I WolfeDepartment of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo/SUNY, Buffalo, New York, USA.ORCID https://orcid.org/0000-0003-1471-9617
Keren MironDepartment of Neurology, Rambam Medical Center, Haifa, Israel.
Roni Ramon-GonenThe Graduate School of Business Administration, Information Systems Program, Bar-Ilan University, Ramat-Gan, Israel.ORCID https://orcid.org/0000-0002-2529-1567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term health effects of thymectomy in adults remain uncertain. Previous reports suggested associations with increased mortality, cancer incidence, and autoimmune disease, although these findings may reflect differences in patient selection, surgical indication, or follow-up duration. We aimed to examine long-term outcomes following adult thymectomy.

methodsWe performed a propensity score-matched retrospective study of patients who underwent thymectomy or comparator cardiothoracic procedures, with follow-up extending to 10 years. Primary outcomes were all-cause mortality, new-onset malignancy, and autoimmune disease. Findings were compared with those reported in a recent study that has raised caution regarding thymic excision.

resultsWe identified 425 patients who underwent thymectomy and 5401 controls who underwent coronary artery bypass or valve surgery. After matching, 398 patients remained in each group. Thymectomy was not associated with increased mortality at 5 years (HR = 0.63; 95% CI, 0.38-1.04) or 10 years (HR = 0.78; 95% CI, 0.54-1.13). Excluding reclassified thymic cancers, 5-year extrathymic malignancy incidence was 2.3% versus 1.8% (p = 0.54); no significant differences were observed in immune-related disease. Mortality was higher among patients with thymic malignancy. Among MG patients, only one event occurred, precluding reliable estimation.

conclusionsThymectomy was not associated with excess mortality or malignancy at 10 years compared with matched cardiothoracic controls. Indication-stratified analyses within the thymectomy cohort showed higher mortality for thymic malignancy, with insufficient events to assess outcomes in MG patients. These findings do not support a generalized survival penalty from thymectomy, though caution is warranted for incidental thymic removal.

Indexed as

NeoplasmsThymectomyThymus NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedMyasthenia GravisRetrospective Studiescancermortalitymyasthenia gravispropensity score matchingthymectomythymus

Identifiers

PMID42538851
PMCPMC13428259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.